KLK15 and metabolic dysfunction-associated steatohepatitis: In additional, the results showed that LCAD, CPT-1, and ACO had been significantly upregulated in all the SX treatment groups of different dosages with a dose-dependent trend, thereby indicating that SX may protect again NASH by regulating fatty acid β-oxidation.